SCHEMBL2704698

SCHEMBL2704698

COC(=O)c1cnc(Cl)cc1-c1ccc(Cl)cc1

nearest known ligand 0.57

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
SLC6A3 Q01959 5/20 0.57
SLC6A4 P31645 1/20 0.57
MAPT P10636 4/20 0.49
RAB9A P51151 4/20 0.49
SMN1; SMN2 Q16637 4/20 0.49
NPC1 O15118 3/20 0.49
L3MBTL1 Q9Y468 2/20 0.49
NFKB1 P19838 1/20 0.49
NFKB2 Q00653 1/20 0.49
RELA Q04206 1/20 0.49
CNR1 P21554 4/20 0.46
ABL1 P00519 1/20 0.45
KDM4E B2RXH2 3/20 0.43
CYP1A2 P05177 1/20 0.43
CYP2D6 P10635 1/20 0.43
CYP2C9 P11712 1/20 0.43
CYP2C19 P33261 1/20 0.43
LMNA P02545 2/20 0.43
POLB P06746 1/20 0.43
ALDH1A1 P00352 2/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL16635250 0.81 PDE10A (0.43) MAPTLMNA
SCHEMBL977733 0.77 KDM4E (0.49) MAPTRAB9ASMN1; SMN2NPC1ABL1
SCHEMBL29416286 0.77 KDM4E (0.49) MAPTRAB9ASMN1; SMN2NPC1ABL1
SCHEMBL23753718 0.77 KDM4E (0.54) SLC6A3SLC6A4MAPTSMN1; SMN2CNR1
SCHEMBL474122 0.76 KDM4E (0.44) MAPTRAB9ASMN1; SMN2NPC1ABL1
SCHEMBL29551416 0.76 KDM4E (0.44) MAPTRAB9ASMN1; SMN2NPC1ABL1
SCHEMBL5535848 0.76 SLC6A3 (0.65) SLC6A3SLC6A4MAPTRAB9ASMN1; SMN2
SCHEMBL26573424 0.76 SLC6A4 (0.65) SLC6A3SLC6A4MAPTRAB9ASMN1; SMN2
SCHEMBL24501111 0.75 POLQ (0.62)
SCHEMBL30017462 0.75 POLQ (0.62)

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2450350-A1 3-Pyridinecarboxamide and 2-pyrazinecarboxamide derivatives as HDL-cholesterol raising agents F. Hoffmann-La Roche AG (CH) 2012-05-09 EP disclosed